

Accepted Manuscript

Title: Increasing Access to Immuno-Oncology Therapies in Brazil

Authors: Carlos G. Ferreira, Andreia C. Melo, Stephen Stefani, Denizar Vianna, Gustavo Fernandes, Carlos G. Gadelha



PII: S2213-5383(17)30079-6
DOI: <https://doi.org/10.1016/j.jcpo.2017.12.004>
Reference: JCPO 138

To appear in:

Received date: 13-11-2017
Accepted date: 29-12-2017

Please cite this article as: Carlos G.Ferreira, Andreia C.Melo, Stephen Stefani, Denizar Vianna, Gustavo Fernandes, Carlos G.Gadelha, Increasing Access to Immuno-Oncology Therapies in Brazil, Journal of Cancer Policy <https://doi.org/10.1016/j.jcpo.2017.12.004>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Increasing Access to Immuno-Oncology Therapies in Brazil

**Carlos G. Ferreira¹, PhD; Andreia C. Melo^{1,2}, PhD; Stephen Stefani³, PhD;
Denizar Vianna⁴, DSc; Gustavo Fernandes⁵, MD; Carlos G. Gadelha⁶, DSc**

¹ D'Or Institute for Research and Education, Rio de Janeiro/RJ- Brazil.

² Brazilian National Cancer Institute, Rio de Janeiro, Brazil.

³ Mãe de Deus Cancer Center, Porto Alegre, Brazil.

⁴ State University of Rio de Janeiro, Rio de Janeiro/RJ, Brazil.

⁵ Hospital Sírio-Libanês, Unidade Brasília, Brasília, Brazil.

⁶ National School of Public Health, Oswaldo Cruz Foundation, Brasilia, Brazil.

Highlights

- Immuno-oncology has become the fastest growing area in oncology
- In immune-oncology field there is a growing number of effective, but costly agents
- The entire Brazilian public health care system faces serious financial and organizational challenges
- In developing countries the overriding issue is the difficulty of assessing the true value of costly drugs
- We offer recommendations to health policy makers and stakeholders that may improve access and cost

Around the middle of the last century, a scientific understanding of the immune system began to develop. The ability to engineer antibodies and manipulate the molecules of the immune system led to an increasing understanding of how the immune system works [1]. This enabled the development of targeted therapeutic interventions and the rise of what today is termed immuno-oncology.

In recent years, immuno-oncology has become the fastest growing area in oncology and one of the most exciting areas of research and development in all of

Download English Version:

<https://daneshyari.com/en/article/8787317>

Download Persian Version:

<https://daneshyari.com/article/8787317>

[Daneshyari.com](https://daneshyari.com)